Genomic Medicine Sweden
Genomic Medicine Sweden, GMS, is paving the way for improved diagnostics, care and treatment.

News

Long-read genome sequencing: transforming genetic diagnostics for rare diseases
Despite rapid advances in genome and exome sequencing, many individuals with rare diseases remain undiagnosed. In a perspective article published in Nature Genetics, researchers highlight how long-read whole genome sequencing, LR-WGS, offers a paradigm shift in...

The government provides significant new funding to Genomic Medicine Sweden to strengthen precision medicine
The Swedish government announces that it will fund Genomic Medicine Sweden (GMS) with SEK 80 million in 2025. The money will go to continued efforts to develop and sustainably implement precision medicine in healthcare in the areas of cancer, rare diseases and...

Sweden contributes to the EU project Beyond One Million Genome plus
The comprehensive EU project Beyond One Million Genome plus (B1MGplus) has officially started. The new project, funded by the European Commission under the Digital Europe Programme, coordinates and supports the 1+ Million Genomes’ initiative to enable secure access to...
Sweden’s ambitious national collaboration for genomic medicine
Our strategic mission is to foster collaboration between healthcare providers, academia, patient organizations and industry and realize precision medicine by effectively utilizing the rapidly advancing sequencing technologies to provide the highest standards of genomic testing in routine clinical care throughout Sweden.

Healthcare
A close collaboration between healthcare and academia is central in introducing new forms of diagnostics as the basis for an individualized choice of treatment.

Patients & next of kin
Participation and knowledge from patients and next of kin representatives is crucial for GMS to be able to introduce precision medicine in health care based on the individual’s needs.

Industry
Through an active collaboration with industry, GMS will develop and provide tomorrow´s solutions for the diagnostics and treatment of various diseases.

Academia
GMS forms a strong basis for researchers to better understand why disease arises and how new forms of treatment can be developed.
Regional centers
Seven regional centers are the GMS engine
GMS is comprised of seven regional Genomic Medicine Centers (GMC). These joint centers act as the primary point of contact for sequencing patient samples within healthcare, thereby creating an integrated platform for both healthcare delivery and advanced medical research. Each GMC is a collaboration between a region with university hospital care, a university with a faculty of medicine, and SciLifeLab.

Participating partners














In collaboration with



